December 21, 2018 / 7:13 PM / 25 days ago

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 (Reuters) - Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

The results from the study showed the treatment would not achieve superiority in achieving main goal of progression-free survival. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below